Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-297
Derun Li, Hongjun Zhang, Thomas W. Lyons, Theodore A. Martinot, A. Achab, Min-Ping Lu, L. Nogle, S. McMinn, M. Mitcheltree, M. Childers, Q. Pu, Symon Gathiaka, A. Palani, K. Chakravarthy, A. Decastro, J. O’Neil, R. Afshar, N. Walsh, Peter Fan, M. Cheng, Richard A. Miller, Amy C. Doty, R. Palte, Hai-Young Kim, J. Saurí, Adam Beard, Christopher Brynczka, Christian Fischer
{"title":"Abstract 297: Innovation in delivering synthetically challenging bicyclic arginase inhibitors to enhance immunotherapy","authors":"Derun Li, Hongjun Zhang, Thomas W. Lyons, Theodore A. Martinot, A. Achab, Min-Ping Lu, L. Nogle, S. McMinn, M. Mitcheltree, M. Childers, Q. Pu, Symon Gathiaka, A. Palani, K. Chakravarthy, A. Decastro, J. O’Neil, R. Afshar, N. Walsh, Peter Fan, M. Cheng, Richard A. Miller, Amy C. Doty, R. Palte, Hai-Young Kim, J. Saurí, Adam Beard, Christopher Brynczka, Christian Fischer","doi":"10.1158/1538-7445.AM2021-297","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-297","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72678598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-276
Hifzur R Siddique, S. Maurya
{"title":"Abstract 276: Lupeol chemosensitize the cancer stem cells for enzalutamide and ameliorate the enzalutamide induced toxicity in prostate cancer","authors":"Hifzur R Siddique, S. Maurya","doi":"10.1158/1538-7445.AM2021-276","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-276","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"206 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77050297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-20
Yutaro Uchida, T. Matsushima, R. Kurimoto, T. Chiba, Yuki Inutani, H. Asahara
{"title":"Abstract 20: HiBiT tagging system for high throughput chemical screening for chemotherapy","authors":"Yutaro Uchida, T. Matsushima, R. Kurimoto, T. Chiba, Yuki Inutani, H. Asahara","doi":"10.1158/1538-7445.AM2021-20","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-20","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87458791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-270
Jong Oh Kim, E. Choi, S. Jeong, J. Hwang, Eun Sung Jun, Jae-Min Kim, Hong-Mei Zheng, Younghwan Park, Siyoung Jung
{"title":"Abstract 270: Enhanced anti-tumor effect and tolerance of novel irinotecan (sn-38) nanoparticle with double core-shell micelle technology","authors":"Jong Oh Kim, E. Choi, S. Jeong, J. Hwang, Eun Sung Jun, Jae-Min Kim, Hong-Mei Zheng, Younghwan Park, Siyoung Jung","doi":"10.1158/1538-7445.AM2021-270","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-270","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"93 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83863347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-308
Shaloam Dasari, P. Tchounwou, C. Yedjou, R. Brodell, Allison R. Cruse
Skin cancer (SC) is the most common carcinoma affecting 3 million people annually in the United Sates and millions of people worldwide. It is classified as melanoma skin cancer (MSC) and non-melanoma skin cancer (NMSC). NMSC represents approximately 80% of NMSC and includes squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). MSC, however, has a higher mortality rate than SC because of its ability to metastasize. SC is a major health problem in the United States with significant morbidity and mortality in the Caucasian population. Treatment options for SC include cryotherapy, excisional surgery, Mohs surgery, curettage and electrodessication, radiation therapy, photodynamic therapy, immunotherapy, and chemotherapy. Treatments are chosen based on the type of skin cancer and the potential for side effects. Novel targeted therapies are being used with increased frequency for large tumors and for metastatic disease. The objective of this review is to highlight new chemotherapeutic agents that utilize silver nanoparticles in the management of SC. A scoping literature search on PubMed, Google Scholar, and Cancer Registry websites revealed that traditional chemotherapeutic drugs have little effect against SC after the cancer has metastasized. Following a discussion of SC biology, epidemiology, and treatment options, this review focuses on the mechanisms of advanced technologies that use silver nanoparticles in SC treatment regimens. Citation Format: Shaloam R. Dasari, Paul B. Tchounwou, Clement G. Yedjou, Robert T. Brodell, Allison Cruse. Therapeutic implications of silver nanoparticles in the management of skin cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 308.
皮肤癌(SC)是最常见的癌症，每年影响300万美国人和全世界数百万人。它分为黑色素瘤皮肤癌(MSC)和非黑色素瘤皮肤癌(NMSC)。NMSC约占NMSC的80%，包括鳞状细胞癌(SCC)和基底细胞癌(BCC)。然而，由于骨髓间充质干细胞的转移能力，其死亡率高于骨髓间充质干细胞。SC是美国的一个主要健康问题，在高加索人群中发病率和死亡率很高。SC的治疗选择包括冷冻治疗、切除手术、莫氏手术、刮除和电干燥、放射治疗、光动力治疗、免疫治疗和化疗。治疗方法的选择是基于皮肤癌的类型和潜在的副作用。新型靶向治疗越来越多地用于大肿瘤和转移性疾病。本综述的目的是强调利用银纳米颗粒治疗SC的新化疗药物。在PubMed、Google Scholar和Cancer Registry网站上进行了范围广泛的文献检索，发现传统化疗药物对癌症转移后的SC几乎没有作用。在讨论了SC的生物学、流行病学和治疗方案之后，本综述着重讨论了在SC治疗方案中使用纳米银的先进技术的机制。引文格式:Shaloam R. Dasari, Paul B. Tchounwou, Clement G. Yedjou, Robert T. Brodell, Allison Cruse。纳米银在皮肤癌治疗中的应用[摘要]。见:美国癌症研究协会2021年年会论文集;2021年4月10日至15日和5月17日至21日。费城(PA): AACR;癌症杂志，2021;81(13 -增刊):摘要第308期。
{"title":"Abstract 308: Therapeutic implications of silver nanoparticles in the management of skin cancer","authors":"Shaloam Dasari, P. Tchounwou, C. Yedjou, R. Brodell, Allison R. Cruse","doi":"10.1158/1538-7445.AM2021-308","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-308","url":null,"abstract":"Skin cancer (SC) is the most common carcinoma affecting 3 million people annually in the United Sates and millions of people worldwide. It is classified as melanoma skin cancer (MSC) and non-melanoma skin cancer (NMSC). NMSC represents approximately 80% of NMSC and includes squamous cell carcinoma (SCC) and basal cell carcinoma (BCC). MSC, however, has a higher mortality rate than SC because of its ability to metastasize. SC is a major health problem in the United States with significant morbidity and mortality in the Caucasian population. Treatment options for SC include cryotherapy, excisional surgery, Mohs surgery, curettage and electrodessication, radiation therapy, photodynamic therapy, immunotherapy, and chemotherapy. Treatments are chosen based on the type of skin cancer and the potential for side effects. Novel targeted therapies are being used with increased frequency for large tumors and for metastatic disease. The objective of this review is to highlight new chemotherapeutic agents that utilize silver nanoparticles in the management of SC. A scoping literature search on PubMed, Google Scholar, and Cancer Registry websites revealed that traditional chemotherapeutic drugs have little effect against SC after the cancer has metastasized. Following a discussion of SC biology, epidemiology, and treatment options, this review focuses on the mechanisms of advanced technologies that use silver nanoparticles in SC treatment regimens. Citation Format: Shaloam R. Dasari, Paul B. Tchounwou, Clement G. Yedjou, Robert T. Brodell, Allison Cruse. Therapeutic implications of silver nanoparticles in the management of skin cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 308.","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84890552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-LB023
P. Desai, S. Prabhu
Tumor Treating Fields (TTFields) have been clinically proven as safe, effective, and non-invasive approach for cancer treatment. Specifically, TTFields in conjunction with Gemcitabine/nab-Paclitaxel have shown promising results in Phase II pancreatic cancer (PC) PANOVA study. It is imperative to understand here that while TTFields are very safe, concurrent use of anticancer drugs will continue to elicit non-site-specific adverse effects resulting in overall low patient compliance. To overcome this drawback, we have developed an innovative strategy called ‘Tumor Treating Fields Triggered Targeting of Nanoparticles in Cancer (TTFields-TTONIC)9. For this, self-assembling cationic-anionic polymer nanoparticles (S-CAP NPs) encapsulating Gemcitabine as a model anticancer drug were developed. The hypothesis involves combination of NPs and TTFields wherein the developed NPs will be preferentially taken up by the tumor owing to leaky vasculature. Further, only under the applied TTFields, the NPs will be destabilized due to high charge density of cationic and anionic polymers leading to targeted release of encapsulated drug at the tumor site (reduction in non-site-specific side effects). For this, multiple batches of two types of S-CAP NPs [chitosan- bovine serum albumin (Chitosan-BSA) and polyethylenimine- bovine serum albumin (PEI-BSA)] were developed. The formulations were optimized using mathematical modelling and Design Expert® software to achieve low particle size and optimum encapsulation efficiency. Based on the results, 2 formulations from each type i.e., chitosan- BSA S-CAP NPs [Batch C4 - particle size: 210.54 ± 38.96 nm, PDI: 0.194, encapsulation efficiency: 61.26 ± 5.11%, zeta potential: (+) 7.38 ± 3.11; Batch C7 - particle size: 215.67 ± 32.55 nm, PDI: 0.201, encapsulation efficiency: 65.31 ± 5.84 %, zeta potential: (+) 3.22 ± 1.28] and PEI-BSA S-CAP NPs [Batch P5 - particle size: 198.29 ± 41.05 nm, PDI: 0.227, encapsulation efficiency: 58.83 ± 3.33%, zeta potential: (+) 8.17 ± 2.63; Batch P8 - particle size: 209.92 ± 31.33 nm, PDI: 0.196, encapsulation efficiency: 64.31 ± 5.13%, zeta potential: (+) 11.49 ± 2.99] were shortlisted that exhibited particle size ~ 200 nm and encapsulation efficiency in range of 55-65 %. All the formulations exhibited sustained drug release profile over a period of 60 h wherein chitosan- BSA S-CAP NPs showed slower drug release compared to PEI-BSA S-CAP NPs (P Citation Format: Preshita Prafulla Desai, Sunil Prabhu. Drug loaded nanoparticle targeting of pancreatic cancer using tumor treating fields (TTFields) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB023.
{"title":"Abstract LB023: Drug loaded nanoparticle targeting of pancreatic cancer using tumor treating fields (TTFields)","authors":"P. Desai, S. Prabhu","doi":"10.1158/1538-7445.AM2021-LB023","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-LB023","url":null,"abstract":"Tumor Treating Fields (TTFields) have been clinically proven as safe, effective, and non-invasive approach for cancer treatment. Specifically, TTFields in conjunction with Gemcitabine/nab-Paclitaxel have shown promising results in Phase II pancreatic cancer (PC) PANOVA study. It is imperative to understand here that while TTFields are very safe, concurrent use of anticancer drugs will continue to elicit non-site-specific adverse effects resulting in overall low patient compliance. To overcome this drawback, we have developed an innovative strategy called ‘Tumor Treating Fields Triggered Targeting of Nanoparticles in Cancer (TTFields-TTONIC)9. For this, self-assembling cationic-anionic polymer nanoparticles (S-CAP NPs) encapsulating Gemcitabine as a model anticancer drug were developed. The hypothesis involves combination of NPs and TTFields wherein the developed NPs will be preferentially taken up by the tumor owing to leaky vasculature. Further, only under the applied TTFields, the NPs will be destabilized due to high charge density of cationic and anionic polymers leading to targeted release of encapsulated drug at the tumor site (reduction in non-site-specific side effects). For this, multiple batches of two types of S-CAP NPs [chitosan- bovine serum albumin (Chitosan-BSA) and polyethylenimine- bovine serum albumin (PEI-BSA)] were developed. The formulations were optimized using mathematical modelling and Design Expert® software to achieve low particle size and optimum encapsulation efficiency. Based on the results, 2 formulations from each type i.e., chitosan- BSA S-CAP NPs [Batch C4 - particle size: 210.54 ± 38.96 nm, PDI: 0.194, encapsulation efficiency: 61.26 ± 5.11%, zeta potential: (+) 7.38 ± 3.11; Batch C7 - particle size: 215.67 ± 32.55 nm, PDI: 0.201, encapsulation efficiency: 65.31 ± 5.84 %, zeta potential: (+) 3.22 ± 1.28] and PEI-BSA S-CAP NPs [Batch P5 - particle size: 198.29 ± 41.05 nm, PDI: 0.227, encapsulation efficiency: 58.83 ± 3.33%, zeta potential: (+) 8.17 ± 2.63; Batch P8 - particle size: 209.92 ± 31.33 nm, PDI: 0.196, encapsulation efficiency: 64.31 ± 5.13%, zeta potential: (+) 11.49 ± 2.99] were shortlisted that exhibited particle size ~ 200 nm and encapsulation efficiency in range of 55-65 %. All the formulations exhibited sustained drug release profile over a period of 60 h wherein chitosan- BSA S-CAP NPs showed slower drug release compared to PEI-BSA S-CAP NPs (P Citation Format: Preshita Prafulla Desai, Sunil Prabhu. Drug loaded nanoparticle targeting of pancreatic cancer using tumor treating fields (TTFields) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB023.","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78360635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-318
N. Tang, Kristin L Leskoske, K. Garcia-Mansfield, Ritin Sharma, H. Tolson, P. Pirrotte, M. Berens
{"title":"Abstract 318: Multi-omics to edge into precision medicine for DIPG","authors":"N. Tang, Kristin L Leskoske, K. Garcia-Mansfield, Ritin Sharma, H. Tolson, P. Pirrotte, M. Berens","doi":"10.1158/1538-7445.AM2021-318","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-318","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78704610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-291
Martina De Pascale, Chiara Borsari, Erhan Keles, J. A. McPhail, Alexander Schäfer, Rohitha Sriramaratnam, M. Gstaiger, J. Burke, M. Wymann
{"title":"Abstract 291: Development of optimized chemical probes targeting PI3Ka to deconvolute the role of class I PI3Ks isoforms in insulin signaling","authors":"Martina De Pascale, Chiara Borsari, Erhan Keles, J. A. McPhail, Alexander Schäfer, Rohitha Sriramaratnam, M. Gstaiger, J. Burke, M. Wymann","doi":"10.1158/1538-7445.AM2021-291","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-291","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78393502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-296
Sudhir M. Hande, Amber Y. S. Balazs, S. Degorce, K. Embrey, Avipsa Ghosh, Sonja J. Gill, A. Gunnarsson, G. Illuzzi, Jordan Lane, C. Larner, Elisabetta Leo, A. Madin, Lisa McWilliams, M. O’Connor, Jonathan Orme, Fiona Pachl, M. Packer, A. Pike, P. Rawlins, M. Schimpl, A. Staniszewska, Andrew X. Zhang, Xiaolan Zheng, J. Johannes
{"title":"Abstract 296: Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper","authors":"Sudhir M. Hande, Amber Y. S. Balazs, S. Degorce, K. Embrey, Avipsa Ghosh, Sonja J. Gill, A. Gunnarsson, G. Illuzzi, Jordan Lane, C. Larner, Elisabetta Leo, A. Madin, Lisa McWilliams, M. O’Connor, Jonathan Orme, Fiona Pachl, M. Packer, A. Pike, P. Rawlins, M. Schimpl, A. Staniszewska, Andrew X. Zhang, Xiaolan Zheng, J. Johannes","doi":"10.1158/1538-7445.AM2021-296","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-296","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77506893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.1158/1538-7445.AM2021-287
A. Omar, Eman M. El-labbad, A. M. Al-Abd
{"title":"Abstract 287: Design and synthesis of imidazole derivatives as augmented prooxidant anticancer agents","authors":"A. Omar, Eman M. El-labbad, A. M. Al-Abd","doi":"10.1158/1538-7445.AM2021-287","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2021-287","url":null,"abstract":"","PeriodicalId":9563,"journal":{"name":"Cancer Chemistry","volume":"61 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74106547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：